Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Efficacy of Esomeprazole for Non-Allergic Rhinitis: A Double-Blind, Placebo Controlled Trial

This study has been completed.
Information provided by:
University of Texas Southwestern Medical Center Identifier:
First received: August 29, 2008
Last updated: NA
Last verified: August 2008
History: No changes posted
The purpose of this study was to see if high dose esomeprazole (40mg bid) was effective in treating non-allergic rhinitis

Condition Intervention
Vasomotor Rhinitis
Drug: esomeprazole
Drug: placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy of Esomeprazole for Non-Allergic Rhinitis: A Double-Blind, Placebo Controlled Trial

Resource links provided by NLM:

Further study details as provided by University of Texas Southwestern Medical Center:

Primary Outcome Measures:
  • Nasal Symptom scores [ Time Frame: 8 weeks ]

Secondary Outcome Measures:
  • non-nasal symptom scores [ Time Frame: 8 weeks ]
  • reflux scores [ Time Frame: 8 weeks ]
  • quality of life scores [ Time Frame: 8 weeks ]

Enrollment: 43
Study Start Date: June 2005
Study Completion Date: March 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
esomeprazole 40mg po bid
Drug: esomeprazole
40mg by mouth twice daily
Other Name: Nexium
Placebo Comparator: 2 Drug: placebo


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age between 18-80, symptoms of perennial rhinitis, negative epicutaneous skin testing to a panel of common aeroallergens, and ability to speak English

Exclusion Criteria:

  • pregnancy or breast-feeding, evidence of positive skin tests to a common aeroallergen, treatment with a proton pump inhibitor within the month prior to enrollment, treatment with any other anti-reflux therapy within the last month on a daily basis or within the last two weeks on an as needed basis, and other gastrointestinal disorders leading to reflux symptoms
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00745849

United States, Texas
Clinical Trials Office, Aston Building, UT Southwestern
Dallas, Texas, United States, 75390-9016
Sponsors and Collaborators
University of Texas Southwestern Medical Center
Principal Investigator: David A Khan, MD Department of Allergy and Immunology, UT Southwestern
  More Information

Responsible Party: David A. Khan, MD, UT Southwestern Identifier: NCT00745849     History of Changes
Other Study ID Numbers: Efficacy Esomeprazole NAR
Study First Received: August 29, 2008
Last Updated: August 29, 2008

Keywords provided by University of Texas Southwestern Medical Center:
non-allergic rhinitis, laryngopharyngeal reflux

Additional relevant MeSH terms:
Rhinitis, Vasomotor
Common Cold
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017